Glycoengineering-based Glycomedicine Development

Glycoengineering-based Glycomedicine Development

Glycoengineering is a method of improving the properties of proteins by changing their glycosylation. Scientists at CD BioGlyco are experienced in performing carbohydrate-based glycomedicine development and we provide custom glycoengineering-based glycomedicine development services according to your specific needs.

Protein and Antibody Glycoengineering

Many of the proteins found in the biological body have complex carbohydrates. Modification with carbohydrates is increasingly acknowledged as one of the most important "post-translational modifications" determining the fate of the protein, as is the case with phosphorylation. Although the functions of carbohydrates bound to proteins in vivo have not yet been fully clarified, carbohydrates are not mere decoration but are known to contribute greatly to the stabilization of protein structure, improvement in water solubility, and elevation of the degree of diversity and selectivity of bioreactions. In recent years, biopharmaceutical research and development, utilizing the functions of carbohydrates, has been actively carried out.

Since the establishment of monoclonal antibody production using mouse hybridoma technology in the 1980s, there has been expanding progress and continuous technological improvement in the development of therapeutic antibodies. The chimeric, humanized, and fully human technologies broke through the immunogenicity issues of the first-generation mouse monoclonal antibodies. However, there remain unmet needs for the improvement of the efficacy of these therapeutic antibodies. Based on the current understanding of the clinical mechanisms of several therapeutic antibodies, it has been demonstrated that the antibody constant region (Fc)-mediated effector function, especially antibody-dependent cellular cytotoxicity (ADCC), is important for improving the clinical outcome of therapeutic antibodies and that the Fc-linked oligosaccharide structure of the antibody dramatically influences ADCC. Using of glyco-engineered therapeutic antibodies will continue to expand in various clinical areas.

Fig.1 Glycoengineering monoclonal antibodies for enhanced sialylation and glycan-targeted antibody-drug conjugates production.Fig.1 Glycoengineering monoclonal antibodies for enhanced sialylation and glycan-targeted antibody-drug conjugates production. (Buettner, et al., 2018)

Glycoengineering-based Glycomedicine Development Services

CD BioGlyco has been committed to glycomedicine development for many years. We provide our customers with high-quality, cost-effective, and hassle-free customized glycoengineering-based glycomedicine development services. If you are interested in our services, please feel free to contact us.


  1. Buettner, M.J.; et al. Improving immunotherapy through glycodesign. Frontiers in immunology. 2018, 9: 2485.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.